Anti-Nrf2 antibody [EP1808Y],Abcam,AB62352

Anti-Nrf2 antibody [EP1808Y] (ab62352) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF and WB. Anti-Nrf2 antibody [EP1808Y] (ab62352) was first used in a scientific publication in 2009 and has been cited over 584 times in peer reviewed journals. It's performance in Western Blot in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Nrf2 antibody [EP1808Y] (ab62352) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Nrf2 antibody [EP1808Y] (ab62352) has been confirmed by Western Blot testing in Nrf2 knockout HeLa cells ( ab262507 ). Anti-Nrf2 antibody [EP1808Y] (ab62352) has 28 independent reviews from customers. Anti-Nrf2 antibody [EP1808Y] (ab62352) specifically detects Nrf2 (UniProt ID: Q16236; Molecular weight: 68kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EP1808Y - ab180845 . Antibody clone EP1808Y is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 594, PE, APC ( ab194984 , ab194985 , ab206890 , ab223926 , ab223927 ). NRF2 is a pivotal transcription factor in neuro research, known for regulating cellular defense mechanisms. It supports mitochondrial function and protects against oxidative damage, which is crucial for brain health. NRF2 also modulates glial inflammatory responses, playing a significant role in preventing neuroinflammation. Researchers use NRF2 to study oxidative stress, inflammation and neuroprotection, making it essential for understanding and potentially treating neurodegenerative diseases. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Species reactivity Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

Host

Rabbit

Reactivity

Human

Application

Flow Cyt (Intra), ICC/IF, WB

Platform ID

BAB155424654

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Nrf2 antibody [EP1808Y]
Cat. No.AB62352
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationFlow Cyt (Intra), ICC/IF, WB
ClonalityMonoclonal
Clone NumberEP1808Y
Concentration0.727 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Transcription factor that plays a key role in the response to oxidative stress : binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles (PubMed : 11035812, PubMed : 19489739, PubMed : 29018201, PubMed : 31398338). In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex (PubMed : 11035812, PubMed : 15601839, PubMed : 29018201). In response to oxidative stress, electrophile metabolites inhibit activity of the BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2, heterodimerization with one of the small Maf proteins and binding to ARE elements of cytoprotective target genes (PubMed : 19489739, PubMed : 29590092). The NFE2L2/NRF2 pathway is also activated in response to selective autophagy : autophagy promotes interaction between KEAP1 and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex, leading to NFE2L2/NRF2 nuclear accumulation and expression of cytoprotective genes (PubMed : 20452972). The NFE2L2/NRF2 pathway is also activated during the unfolded protein response (UPR), contributing to redox homeostasis and cell survival following endoplasmic reticulum stress (By similarity). May also be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region (PubMed : 7937919). Also plays an important role in the regulation of the innate immune response and antiviral cytosolic DNA sensing. It is a critical regulator of the innate immune response and survival during sepsis by maintaining redox homeostasis and restraint of the dysregulation of pro-inflammatory signaling pathways like MyD88-dependent and -independent and TNF signaling (By similarity). Suppresses macrophage inflammatory response by blocking pro-inflammatory cytokine transcription and the induction of IL6 (By similarity). Binds to the proximity of pro-inflammatory genes in macrophages and inhibits RNA Pol II recruitment. The inhibition is independent of the NRF2-binding motif and reactive oxygen species level (By similarity). Represses antiviral cytosolic DNA sensing by suppressing the expression of the adapter protein STING1 and decreasing responsiveness to STING1 agonists while increasing susceptibility to infection with DNA viruses (PubMed : 30158636). Once activated, limits the release of pro-inflammatory cytokines in response to human coronavirus SARS-CoV-2 infection and to virus-derived ligands through a mechanism that involves inhibition of IRF3 dimerization. Also inhibits both SARS-CoV-2 replication, as well as the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism (PubMed : 33009401). See full target information NFE2L2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.